Host-derived CCL5 is Critical for Mammary Tumor Growth and Metastasis (50.30)

Jianguo Liu,Xiaojing Ma

DOI: https://doi.org/10.4049/jimmunol.178.supp.50.30

2007-01-01

The Journal of Immunology

Abstract:CCL5 is a chemokine produced by a variety of human cells under stress. It plays an important role in inflammation by recruiting T cells, macrophages and eosinophils to inflammatory sites. It has been shown in animal studies that tumor-derived CCL5 is able to help tumors to form new blood vessels (angiogenesis), thus fostering their growth. Tumor-derived CCL5 can also inhibit the T cell response and enhance the growth of breast cancer. Human studies have shown high incidence of CCL5 expression in tissue sections of breast carcinomas. Furthermore, in stage II breast cancer patients, the expression of CCL5 increased significantly the risk for disease progression. However, the mechanisms of CCL5 promote the tumor growth and metastasis is still unknown. Using a syngeneic 4T1 mammary tumor model that closely resembles human breast cancer in primary tumor growth characteristics and metastatic properties, we have observed that, compared to control wild type mice of identical background, mice that are genetically deficient in CCL5 (CCL5-ko) are highly resistant to 4T1 tumor growth and to tumor-induced death. In addition, the remaining tumors in CCL5-ko mice developed little lung metastasis after 60 days. The CCL5-ko mice that regressed the tumor promptly and strongly rejected rechallenge with 4T1 tumor, indicating establishment of protective immunity. Furthermore, mAb-mediated neutralization of CCL5 in vivo prevented 4T1 tumor growth and lung metastasis. Our data also indicate that 4T1 tumor cells spontaneously produce high levels of CCL5 driven by highly active NF-kB and other yet to be characterized transcription factors. In conclusion, CCL5 plays a critical role in the growth and metastasis of mammary tumors, and that CCL5 represents a desirable and accessible target in breast cancer therapy.